Actuate Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Actuate Therapeutics (ACTU) with a Buy rating and $20 price target Actuate is a clinical-stage biotechnology company developing novel glycogen synthase kinase-3 inhibitors for cancer treatment, the analyst tells investors in a research note. The firm says strong interim Phase 2 data for elraglusib in metastatic pancreatic cancer bode well for the Q2 readout.